GLTO galecto.com Earnings growth forecast for next year

Corporate emblem and logo of Galecto (GLTO)

Galecto, Inc. (GLTO) is developing unique galectin inhibitors to combat cancer and fibrosis, leveraging its patent protection. Shifting analyst estimates for EPS growth visualize this process, with the parameter value reaching -11.90. Future prospects depend on the efficacy of metabolic drugs and strategic partnerships. The company is currently restructuring its pipeline and workforce following unsuccessful tests while maintaining a sufficient liquidity cushion.

Galecto Corp (GLTO): Expected net earnings per share growth next year from 07/04/2022 to 03/10/2026

GLTO (galecto.com): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Stock Price Galecto Corp|GLTO - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Galecto|GLTO - Total Company Value
- book capitalization indicators:
Net Assets per Single Share Galecto|GLTO - Total Stockholders' Equity|Market Value to Book Value Ratio galecto.com|GLTO - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Galecto, Inc.|GLTO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Galecto|GLTO - Company Total Debt Obligations|Debt to Book Capitalization Ratio Galecto|GLTO - Company Long-Term Liabilities|Company Short-Term Debts Galecto|Quick Ratio galecto.com
- net income and valuation ratios data:
GLTO - Net Profit|Expected Profit Galecto, Inc.|GLTO - Price to Earnings Ratio|Forward P/E Multiple Galecto, Inc.|GLTO - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Galecto|GLTO - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Galecto|GLTO - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months galecto.com|GLTO - Earnings per share growth rate in current year|Expected earnings per share growth for next year Galecto, Inc.
Initial company analysis:GLTO, Galecto Corp
Finished products of Galecto

Galecto, Inc. (GLTO) development of unique selective galectin inhibitors to combat fibrosis defines the trajectory of the consensus EPS n+1 forecast chart, which currently stands at -11.90. This indicator measures the weighted average analyst expectation for earnings per share changes, where a steady upward curve confirms the company's strong pricing power in an inelastic market and market confidence in the future monetization of its drugs.

Analysis of competing companies

ASND (Ascendis Pharma Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Corp|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (rhythmtx.com)|Net earnings per share growth forecast for next year Akero AKRO|Metsera, Inc. (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Therapeutics, Inc.|89bio Inc (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Agios Pharmaceuticals Inc (AGIO)|Expected earnings per share growth for next year Structure Corp GPCR|Earnings growth forecast for next year MDXG (MiMedx Group, Inc.)|Net earnings per one share growth forecast for next year rezolutebio.com|Lexicon Pharmaceuticals, Inc. - Earnings growth forecast for next year|MBX - Earnings growth forecast for next year|Altimmune Corp (ALT) - Net earnings per share growth forecast for next year|AARD (Aardvark Pharma) - Net earnings per share growth forecast for next year|SGMT (Sagimet Biosciences) - Earnings growth forecast for next year|Expected net earnings per share growth next year bioagelabs.com BIOA|Earnings growth forecast for next year BMEA|Expected earnings per share growth for next year quincetx.com QNCX|Fractyl - Expected earnings per share growth for next year|Projected earnings per share increase next year VTVT (vTv Therapeutics, Inc.)|ATPC - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Pluri Inc.|SYBX (synlogictx.com) - Expected earnings per share growth for next year|Lipocine Inc - Expected earnings per share trend next year|MTNB (Matinas BioPharma Holdings, Inc.) - Earnings growth forecast for next year|Spruce Biosciences Inc. (SPRB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Corporation (CTCX)|lumos-pharma.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year ONVO (Organovo)|RDUS - Expected earnings per share growth for next year